AVIRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Atea Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$4.39+0.07 (+1.62%)
Close on Oct 19, 2026
- Market cap
- $351.42M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
74.1%
59M of 80M shares
Institutional holders
125
19 new, 20 sold out
Net institutional buying
-1M
In Q2 2026
Insider trades, 12 months
1 buys · 0 sales
Net bought $25.44K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Abigail P. Johnson | 9,095,680 | 11.60% | 13G (passive) amendment | Nov 28, 2025 |
| Jean-Pierre Sommadossi | 8,876,453 | 10.10% | 13G (passive) amendment | Mar 31, 2025 |
| Leonard Braden Michael | 7,810,000 | 9.90% | 13G (passive) | Dec 31, 2025 |
| BlackRock, Inc. | 6,082,350 | 7.10% | 13G (passive) amendment | Mar 31, 2025 |
| Kevin Tang | 4,814,700 | 6.00% | 13G (passive) | Oct 6, 2026 |
| FMR LLC | 11,950,772 | 15.00% | 13G (passive) amendment | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of AVIR | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 12,004,064 | 14.97% | $55.82M | +53,292 | 0.00% |
| BlackRock, Inc. | 8,720,077 | 10.87% | $40.55M | +284,640 | 0.00% |
| BML Capital Management, LLC | 6,952,330 | 8.67% | $32.33M | −106,327 | 18.36% |
| Tang Capital Management LLC | 4,814,700 | 6.00% | $22.39M | – | 1.02% |
| Vanguard Capital Management LLC | 2,964,862 | 3.70% | $13.79M | −281,262 | 0.00% |
| Bain Capital Life Sciences Investors, LLC | 2,075,639 | 2.59% | $9.65M | −284,999 | 0.57% |
| Acadian Asset Management LLC | 2,035,192 | 2.54% | $9.46K | +452,375 | 0.01% |
| Geode Capital Management, LLC | 1,958,435 | 2.44% | $9.11M | +210,729 | 0.00% |
| State Street Corp | 1,652,399 | 2.06% | $7.68M | −42,236 | 0.00% |
| Two Sigma Investments, LP | 1,506,697 | 1.88% | $7.01M | −357,467 | 0.01% |
| Dimensional Fund Advisors LP | 1,299,515 | 1.62% | $6.04M | +44,031 | 0.00% |
| Renaissance Technologies LLC | 1,131,200 | 1.41% | $5.26M | −35,200 | 0.01% |
| Rosalind Advisors, Inc. | 1,070,550 | 1.33% | $4.98M | −101,305 | 1.85% |
| JPMorgan Chase & Co | 945,918 | 1.18% | $4.36M | +5,761 | 0.00% |
| Northern Trust Corp | 755,239 | 0.94% | $3.51M | +170,214 | 0.00% |
| Morgan Stanley | 719,514 | 0.90% | $3.35M | −11,506 | 0.00% |
| Vanguard Portfolio Management LLC | 630,185 | 0.79% | $2.93M | +72,606 | 0.00% |
| Charles Schwab Investment Management Inc | 610,607 | 0.76% | $2.84M | +13,898 | 0.00% |
| Goldman Sachs Group Inc | 530,856 | 0.66% | $2.47M | −57,607 | 0.00% |
| Vanguard Fiduciary Trust Co | 469,801 | 0.59% | $2.18M | −14,904 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 125 | 59M | 74.1% | 19 / 46 | 38 / 20 | 3M | 3M |
| Q1 2026 | 127 | 60M | 74.9% | 27 / 38 | 40 / 10 | 11M | 4M |
| Q4 2025 | 111 | 57M | 71.4% | 11 / 31 | 43 / 12 | 7M | 3M |
| Q3 2025 | 115 | 54M | 67.1% | 15 / 34 | 38 / 6 | 3M | 2M |
| Q2 2025 | 106 | 53M | 65.7% | 13 / 36 | 28 / 10 | 2M | 2M |
| Q1 2025 | 103 | 53M | 66.0% | 9 / 37 | 36 / 11 | 2M | 5M |
| Q4 2024 | 106 | 56M | 70.2% | 14 / 38 | 32 / 16 | 3M | 5M |
| Q3 2024 | 108 | 58M | 72.3% | 15 / 40 | 29 / 11 | 11M | 1M |
| Q2 2024 | 105 | 57M | 70.7% | 13 / 36 | 37 / 21 | 5M | 3M |
| Q1 2024 | 113 | 55M | 68.9% | 19 / 35 | 38 / 14 | 3M | 4M |
| Q4 2023 | 108 | 56M | 69.3% | 11 / 45 | 30 / 21 | 5M | 5M |
| Q3 2023 | 119 | 57M | 70.9% | 6 / 44 | 42 / 20 | 6M | 6M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of AVIR | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Growth Company Fund | 3,102,958 | 3.87% | $14.49M | 0.01% | May 31, 2026 |
| Vanguard Total Stock Market Index Fund | 2,032,268 | 2.53% | $9.45M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,835,401 | 2.29% | $8.53M | 0.01% | Jun 30, 2026 |
| Fidelity Growth Company K6 Fund | 1,217,814 | 1.52% | $5.69M | 0.02% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 865,318 | 1.08% | $4.02M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 771,325 | 0.96% | $3.63M | 0.01% | Jul 31, 2026 |
| Fidelity Series Growth Company Fund | 733,900 | 0.92% | $3.43M | 0.01% | May 31, 2026 |
| iShares Russell 2000 Value ETF | 669,481 | 0.83% | $3.11M | 0.02% | Jun 30, 2026 |
| BlackRock Advantage Small Cap Core Fund | 613,370 | 0.76% | $2.86M | 0.05% | May 29, 2026 |
| iShares Biotechnology ETF | 437,948 | 0.55% | $2.04M | 0.02% | Jun 30, 2026 |
| Vanguard Russell 2000 Index Fund | 358,829 | 0.45% | $1.68M | 0.01% | May 31, 2026 |
| U.S. Small Cap Portfolio | 349,976 | 0.44% | $1.64M | 0.01% | Jul 31, 2026 |
| Schwab U.S. Small-Cap ETF | 345,893 | 0.43% | $1.62M | 0.01% | May 31, 2026 |
| Fidelity Extended Market Index Fund | 313,724 | 0.39% | $1.47M | 0.00% | May 31, 2026 |
| Select Biotechnology Portfolio | 287,662 | 0.36% | $1.34M | 0.03% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Jean-Pierre Sommadossi | President, CEO, and Chairman, Director | 6,633,855 | 8.27% | Feb 3, 2026 |
| Andrea Corcoran | See Remarks | 823,576 | 1.03% | Mar 13, 2026 |
| Janet MJ Hammond | Chief Development Officer | 127,665 | 0.16% | Feb 3, 2026 |
| Wayne Foster | EVP, Chief Accounting Officer | 91,461 | 0.11% | Feb 3, 2026 |
| Maria Arantxa Horga | Chief Medical Officer | 112,159 | 0.14% | Feb 3, 2026 |
| John Vavricka | Chief Commercial Officer | 176,672 | 0.22% | Feb 3, 2026 |
| Jerome M. Adams | Director | 92,350 | 0.12% | Jun 23, 2026 |
| Arthur S. Kirsch | Director | 45,710 | 0.06% | Jun 23, 2026 |
| Howard Berman | Director | – | – | Jun 23, 2026 |
| Franklin M. Berger | Director | 536,097 | 0.67% | Jun 23, 2026 |
| Barbara Gayle Duncan | Director | 92,350 | 0.12% | Jun 23, 2026 |
| Bruno Lucidi | Director | 142,350 | 0.18% | Jun 23, 2026 |
| Bruce Polsky | Director | 124,806 | 0.16% | Jun 23, 2026 |
| Polly A. Murphy | Director | 133,040 | 0.17% | Jun 23, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Barbara Gayle Duncan Director | Jun 18, 2026 | Option exercise | +29,600 | – | – | 92,350 |
| Franklin M. Berger Director | Jun 18, 2026 | Option exercise | +29,600 | – | – | 536,097 |
| Jerome M. Adams Director | Jun 18, 2026 | Option exercise | +29,600 | – | – | 92,350 |
| Bruno Lucidi Director | Jun 18, 2026 | Option exercise | +29,600 | – | – | 142,350 |
| Polly A. Murphy Director | Jun 18, 2026 | Option exercise | +29,600 | – | – | 121,745 |
| Bruce Polsky Director | Jun 18, 2026 | Option exercise | +29,600 | – | – | 124,806 |
| Polly A. Murphy Director | May 18, 2026 | Buy | +6,100 | $4.17 | $25.44K | 92,145 |
| Andrea Corcoran See Remarks | Mar 11, 2026 | Option exercise | +60,000 | $1.24 | $74.40K | 823,576 |
| Jean-Pierre Sommadossi President, CEO, and Chairman, Director | Feb 3, 2026 | Option exercise | +300,000 | $1.24 | $372.00K | 767,830 |
| John Vavricka Chief Commercial Officer | Jan 31, 2026 | Option exercise | +42,083 | – | – | 94,164 |
| John Vavricka Chief Commercial Officer | Jan 31, 2026 | Tax withholding | −11,570 | $4.24 | $49.06K | 82,594 |
| Jean-Pierre Sommadossi President, CEO, and Chairman, Director | Jan 31, 2026 | Option exercise | +272,983 | – | – | 573,923 |
| Jean-Pierre Sommadossi President, CEO, and Chairman, Director | Jan 31, 2026 | Tax withholding | −106,093 | $4.24 | $449.83K | 467,830 |
| Maria Arantxa Horga Chief Medical Officer | Jan 31, 2026 | Option exercise | +51,283 | – | – | 112,159 |
| Maria Arantxa Horga Chief Medical Officer | Jan 31, 2026 | Tax withholding | −16,073 | $4.24 | $68.15K | 96,086 |
| Andrea Corcoran See Remarks | Jan 31, 2026 | Tax withholding | −16,104 | $4.24 | $68.28K | 763,576 |
| Andrea Corcoran See Remarks | Jan 31, 2026 | Option exercise | +54,866 | – | – | 779,680 |
| Janet MJ Hammond Chief Development Officer | Jan 31, 2026 | Tax withholding | −14,136 | $4.24 | $59.94K | 127,665 |
| Janet MJ Hammond Chief Development Officer | Jan 31, 2026 | Option exercise | +58,050 | – | – | 141,801 |
| Wayne Foster EVP, Chief Accounting Officer | Jan 31, 2026 | Option exercise | +41,333 | – | – | 91,461 |
| Wayne Foster EVP, Chief Accounting Officer | Jan 31, 2026 | Tax withholding | −12,132 | $4.24 | $51.44K | 79,329 |
| Jerome M. Adams Director | Jun 20, 2025 | Option exercise | +29,600 | – | – | 62,750 |
| Bruce Polsky Director | Jun 20, 2025 | Option exercise | +29,600 | – | – | 95,206 |
| Barbara Gayle Duncan Director | Jun 20, 2025 | Option exercise | +29,600 | – | – | 62,750 |
| Franklin M. Berger Director | Jun 20, 2025 | Option exercise | +29,600 | – | – | 506,497 |
| Polly A. Murphy Director | Jun 20, 2025 | Option exercise | +29,600 | – | – | 86,045 |
| Bruno Lucidi Director | Jun 20, 2025 | Option exercise | +29,600 | – | – | 112,750 |
| Polly A. Murphy Director | May 18, 2025 | Buy | +6,100 | $4.17 | $25.44K | 92,145 |
| Jean-Pierre Sommadossi President, CEO, and Chairman, Director | Jan 31, 2025 | Tax withholding | −88,601 | $3.06 | $271.12K | 300,940 |
| Jean-Pierre Sommadossi President, CEO, and Chairman, Director | Jan 31, 2025 | Option exercise | +173,467 | – | – | 290,024 |
| Jean-Pierre Sommadossi President, CEO, and Chairman, Director | Jan 31, 2025 | Award | +99,517 | – | – | 389,541 |
| John Vavricka Chief Commercial Officer | Jan 31, 2025 | Tax withholding | −11,517 | $3.06 | $35.24K | 52,081 |
| John Vavricka Chief Commercial Officer | Jan 31, 2025 | Option exercise | +33,333 | – | – | 54,848 |
| John Vavricka Chief Commercial Officer | Jan 31, 2025 | Award | +8,750 | – | – | 63,598 |
| Janet MJ Hammond Chief Development Officer | Jan 31, 2025 | Award | +11,250 | – | – | 95,522 |
| Janet MJ Hammond Chief Development Officer | Jan 31, 2025 | Tax withholding | −14,134 | $3.06 | $43.25K | 81,388 |
| Janet MJ Hammond Chief Development Officer | Jan 31, 2025 | Option exercise | +46,800 | – | – | 84,272 |
| Wayne Foster EVP, Chief Accounting Officer | Jan 31, 2025 | Tax withholding | −12,062 | $3.06 | $36.91K | 50,128 |
| Wayne Foster EVP, Chief Accounting Officer | Jan 31, 2025 | Award | +8,000 | – | – | 62,190 |
| Wayne Foster EVP, Chief Accounting Officer | Jan 31, 2025 | Option exercise | +33,333 | – | – | 54,190 |
| Andrea Corcoran See Remarks | Jan 31, 2025 | Option exercise | +44,367 | – | – | 722,909 |
| Andrea Corcoran See Remarks | Jan 31, 2025 | Award | +10,500 | – | – | 733,409 |
| Andrea Corcoran See Remarks | Jan 31, 2025 | Tax withholding | −16,102 | $3.06 | $49.27K | 717,307 |
| Maria Arantxa Horga Chief Medical Officer | Jan 31, 2025 | Option exercise | +41,533 | – | – | 67,197 |
| Maria Arantxa Horga Chief Medical Officer | Jan 31, 2025 | Tax withholding | −16,071 | $3.06 | $49.18K | 60,876 |
| Maria Arantxa Horga Chief Medical Officer | Jan 31, 2025 | Award | +9,750 | – | – | 76,947 |
| Franklin M. Berger Director | Jan 16, 2025 | Buy | −10,000 | $3.36 | $33.60K | 476,897 |
| Franklin M. Berger Director | Jan 16, 2025 | Buy | +10,000 | $3.36 | $33.60K | 476,897 |
| Franklin M. Berger Director | Jan 15, 2025 | Buy | −15,000 | $3.19 | $47.85K | 466,897 |
| Franklin M. Berger Director | Jan 15, 2025 | Buy | +15,000 | $3.19 | $47.85K | 466,897 |
| Franklin M. Berger Director | Dec 10, 2024 | Sale | −359,606 | $2.85 | $1.02M | 451,897 |
| Jean-Pierre Sommadossi President, CEO, and Chairman, Director | Sep 19, 2024 | Sale(10b5-1 plan) | −1,841 | $4.00 | $7.36K | 5,866,025 |
| Jean-Pierre Sommadossi President, CEO, and Chairman, Director | Sep 18, 2024 | Sale(10b5-1 plan) | −22,187 | $4.03 | $89.41K | 5,867,866 |
| Jean-Pierre Sommadossi President, CEO, and Chairman, Director | Sep 17, 2024 | Sale(10b5-1 plan) | −33,941 | $4.05 | $137.46K | 5,890,053 |
| Bruce Polsky Director | Jun 20, 2024 | Sale | −17,544 | $3.49 | $61.23K | 65,606 |
| Polly A. Murphy Director | Jun 16, 2024 | Option exercise | +33,150 | – | – | 56,445 |
| Bruno Lucidi Director | Jun 16, 2024 | Option exercise | +33,150 | – | – | 83,150 |
| Bruce Polsky Director | Jun 16, 2024 | Option exercise | +33,150 | – | – | 83,150 |
| Franklin M. Berger Director | Jun 16, 2024 | Option exercise | +33,150 | – | – | 811,503 |
| Barbara Gayle Duncan Director | Jun 16, 2024 | Option exercise | +33,150 | – | – | 33,150 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Berger Franklin Lead Independent Director | Dec 10, 2024 | 359,606 | $1.02M | Dec 10, 2024 | Investment |
| Partners LLC JPM Affiliate | Sep 19, 2024 | 1,841 | $7.37K | Sep 19, 2024 | Founder Shares |
| Partners LLC JPM Affiliate | Sep 18, 2024 | 22,187 | $89.47K | Sep 18, 2024 | Founder Shares |
| Partners LLC JPM Affiliate | Sep 17, 2024 | 33,941 | $137.32K | Sep 17, 2024 | Founder Shares |
| Bruce Polsky Director | Jun 20, 2024 | 17,544 | $68.77K | Jun 20, 2024 | RESTRICTED STOCK |
| Partners LLC JPM Affiliate | Jun 5, 2024 | 1,006 | $4.02K | Jun 5, 2024 | Founder Shares |
| Vavricka John Chief Commercial Officer | Feb 1, 2024 | 13,552 | $55.16K | Feb 1, 2024 | Shares acquired upon vesting of restricted stock units awarded under Issuer's 2020 Incentive Award Plan |
| Corcoran Andrea CFO, EVP, Legal and Secretary | Feb 1, 2024 | 18,198 | $74.07K | Feb 1, 2024 | Shares acquired upon vesting of restricted stock units awarded under Issuer's 2020 Incentive Award Plan |
| Sommadossi Jean-Pierre President, CEO, and Chairman | Feb 1, 2024 | 65,476 | $266.49K | Feb 1, 2024 | Shares acquired upon vesting of restricted stock units awarded under Issuer's 2020 Incentive Award Plan |
| MJ Hammond Janet Chief Development Officer | Feb 1, 2024 | 16,110 | $65.57K | Feb 1, 2024 | Shares acquired upon vesting of restricted stock units awarded under Issuer's 2020 Incentive Award Plan |
| Foster Wayne EVP, Chief Accounting Officer | Feb 1, 2024 | 14,311 | $58.25K | Feb 1, 2024 | Shares acquired upon vesting of restricted stock units awarded under Issuer's 2020 Incentive Award Plan |
| Arantxa Horga Maria Chief Medical Officer | Feb 1, 2024 | 18,227 | $74.18K | Feb 1, 2024 | Shares acquired upon vesting of restricted stock units awarded under Issuer's 2020 Incentive Award Plan |